Seres therapeutics reports third quarter 2023 financial results including vowst™ net sales of $7.6 million

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today reported financial results for the third quarter ended september 30, 2023, including vowst net sales of $7.6 million. third quarter vowst commercial results show strong continued progress, driven by a significant increase in new patient starts and exceeding the company's forecasted expectations across multiple dimensions. vowst is indicated to prevent the recurrence of cl.
MCRB Ratings Summary
MCRB Quant Ranking